Do PML/RAR-alpha isoforms have clinical significance in patients with acute promyeloctyic leukemia?.
- Author:
Hyeon Seok EOM
1
Author Information
1. Hematology-Oncology Clinic, National Cancer Center, Seoul, Korea.
- Publication Type:Editorial
- Keywords:
Acute promyelocytic leukemia;
PML/RAR-alpha isoform
- MeSH:
Exons;
Humans;
Incidence;
Introns;
Leukemia;
Leukemia, Promyelocytic, Acute;
Protein Isoforms;
Recurrence;
RNA Isoforms;
RNA, Messenger;
Tretinoin
- From:Korean Journal of Medicine
2008;75(4):409-411
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Acute promyelocytic leukemia (APL) is characterized by a specific t (15;17) translocation which produce a PML/RAR-alpha fusion messenger RNA and by effectiveness of all-trans retinoic acid (ATRA) differentiation therapy. Breakpoints within PML intron 3 (bcr 3) produce a short PML/RAR-alpha isoform (S-isoform), whereas breakpoints within PML intron 6 (bcr 1) result in a longer form (L-isoform). Additionally, breakpoints within PML exon 6 (bcr 2) make a variable length transcript (V-isoform) in a small number of patients. The influence of breakpoint site on patient outcome remains controversial. Previous reports showed that patients with S-isoform have an increased incidence of clinical relapse and shorter survival compared to those with L-isoform. Others reported no difference in DFS between these patients groups. In this issue, Lee et al. reported that there were 58 L-isoform (62.1%), 32 S-isoform (34.0%), 4 V-isoform (4.3%) and, no significant prognostic factor for EFS from induction therapy using anthracycline plus ATRA among 94 patients with APL. They concluded pretreatment clinical characteristics and treatment outcomes were not significantly different according to PML/RAR-alpha isoform types in this induction group. Recently, it was reported that FLT3/ITD mutation was frequently associated with S-isoform and with the M3v form of leukemia and CNS relapse in APL was mostly related to S-isoform. With previous studies including this article, outcomes of different types of PML/RAR-alpha isoforms are not conclusive. Future researches need to be focused not only on clinical outcomes of different types of PML/RAR-alpha isoforms, but also clinical relevance of PML/RARA-alpha mRNA isoforms with other prognostic factors and particular clinical characteristics.
